IR News
Sep. 01, 2020Print(PDF/123KB)Corporate
Sumitomo Dainippon Pharma Announces Organizational Realignment and Change in Executive Officer
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following organizational realignment and change in Executive Officer, effective October 1, 2020:
I. Organizational Realignment (effective October 1, 2020)
Sales & Marketing (Division)
CNS Sales Department is created and Psychiatry Groups belonging to Branches are transferred to CNS Sales Department.*
＊ By improving the efficiency of information sharing as well as instruction transmission, and also by developing a unified strategy, we will strengthen the organization toward becoming a leading pharmaceutical company in Psychiatry & Neurology area in Japan.
II. Change in Executive Officer
Change in the position assumed by Executive Officer (effective October 1, 2020)
| Position as of October 1, 2020 | Current position | Name |
|---|---|---|
|
Member, Board of Directors, Executive Vice President Executive Director, Sales & Marketing Division Senior Director, CNS Sales Department Head of Japan Business Unit |
Member, Board of Directors, Executive Vice President Executive Director, Sales & Marketing Division Head of Japan Business Unit |
Hitoshi Odagiri |